Basilea Pharmaceutica AG (LON:0QNA)
58.53
+0.67 (1.16%)
Feb 12, 2026, 5:09 PM GMT
Basilea Pharmaceutica AG Revenue
Basilea Pharmaceutica AG had revenue of 103.96M CHF in the half year ending June 30, 2025, with 22.44% growth. This brings the company's revenue in the last twelve months to 236.21M, up 58.51% year-over-year. In the year 2024, Basilea Pharmaceutica AG had annual revenue of 208.54M with 32.30% growth.
Revenue (ttm)
236.21M CHF
Revenue Growth
+58.51%
P/S Ratio
3.12
Revenue / Employee
1.31M CHF
Employees
180
Market Cap
676.01M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 208.54M | 50.91M | 32.30% |
| Dec 31, 2023 | 157.63M | 9.87M | 6.68% |
| Dec 31, 2022 | 147.77M | -357.00K | -0.24% |
| Dec 31, 2021 | 148.12M | 20.49M | 16.06% |
| Dec 31, 2020 | 127.63M | -6.75M | -5.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Spire Healthcare Group | 1.55B |
| CVS Group | 673.20M |
| Advanced Medical Solutions Group | 220.30M |
| Oxford Nanopore Technologies | 204.69M |
Basilea Pharmaceutica AG News
- 4 weeks ago - Basilea Pharmaceutica Partners With INCATE To Advance Antibacterial And Antifungal Innovation - Nasdaq
- 5 weeks ago - Basilea provides portfolio update and outlook - GlobeNewsWire
- 5 weeks ago - Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections - PRNewsWire
- 2 months ago - Basilea partners with Phare Bio to deploy generative AI for antibiotic discovery - Seeking Alpha
- 2 months ago - Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic - GlobeNewsWire
- 2 months ago - Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI - Business Wire
- 3 months ago - Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea - GlobeNewsWire
- 5 months ago - Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam - GlobeNewsWire